Navigation Links
Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
Date:7/21/2009

JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed's first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed's trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients.

Oramed's oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion.

Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results demonstrate that Oramed's oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal."

Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193
    Int'l: +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
2. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
3. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
4. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
5. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
6. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
7. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
8. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
9. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... The Society for Immunotherapy of ... outlined in the Administration’s recently published fiscal year 2018 budget request. , ... Health (NIH) by $5.8 billion or roughly 20% of its total budget. If applied ...
(Date:3/22/2017)... March 22, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Officer, will present at the 5th Annual Cancer ... a platform to present to and meet with ... and biotech companies as well as institutional investors. ...
(Date:3/20/2017)... ... March 20, 2017 , ... HOLLOWAY AMERICA, a ... announced it will debut a brand new pressure vessel, the intelliVessel™, at INTERPHEX ... by a touch screen panel and features other revolutionary operations that promote safer, ...
(Date:3/20/2017)... ... ... The fourth annual Hackaday Prize , which aims to expand the ... lives, launches today. Sponsored by Digi-Key and Microchip , the competition ... prizes to engineers, inventors and tinkerers who “build something that matters.” , The first ...
Breaking Biology Technology:
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):